IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With IQVIA Pty Ltd, Premier Inc.
Phase
Phase 4
Status
Withdrawn
Study type
Interventional
Design
Na · None · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Recruitment challenges
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-19 | estimated | When the study began enrolling |
| Primary completion | 2025-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-02-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COPD
Interventions
- Drug: Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.
- Other: External Comparator
Primary outcome
what the primary-completion date above is the date OFProportion of patients with an all-cause readmission
measured 90 days post-index discharge
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed